This list is an analysis based on recent market events. It's not an investment recommendation.
About
Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, such as cardiovascular issues, metabolic disorders, neurological ailments, obstetric and gynecological health, respiratory diseases, andrological concerns, immunological responses, as well as antibiotics and anti-cancer therapies. Beyond prescription drugs, the company offers nutritional and infant care items, including specialized milk formulas and dietary supplements, marketed under the brand names Karihome, Babecare, and Ostricare. Additionally, it supplies health-related supplements, notably Buccotherm-branded thermal water, designed for the management of oral and periodontal conditions. The company's diverse product range extends to skincare, featuring items like essences, creams, lotions, eye creams, facial toners, and skin-repairing treatments available through its AGLab line. It also distributes skincare oils, body lotions, and gels for dry skin under the well-known Bio-Oil brand, and markets children's skincare solutions through the Mister Baby brand. Furthermore, OEP oversees ISISPHARMA, a dermatology laboratory dedicated to the creation and distribution of specialized dermo-cosmetic goods. Orient EuroPharma is actively involved in extensive research and development efforts, with several key compounds in its pipeline. These include Multikine, an immunotherapy treatment for head and neck cancer currently undergoing Phase III clinical trials; NC-6004, a platinum-based micelle chemotherapeutic agent also in Phase III; ASC-J9, a molecular chemical entity targeting androgen receptor degradation, which has successfully finished its Phase IIb clinical study; and 2ccPA, a phospholipid derivative for symptomatic knee osteoarthritis, progressing through Phase I clinical trials. Established in 1982, Orient EuroPharma Co., Ltd. maintains its headquarters in Taipei, Taiwan.
The current price of 4120.TWO is TWD42.50 TWD — it has decreased by -0.58% in the past 24 hours. Watch Orient Europharma. stock price performance more closely on the chart.
What is Orient Europharma. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Taiwan OTC Exchange exchange Orient Europharma. stocks are traded under the ticker 4120.TWO.
Is Orient Europharma. stock price growing?▼
4120.TWO stock has fallen by -5.03% compared to the previous week, the month change is a -7.81% fall, over the last year Orient Europharma. has showed a -8.8% decrease.
What is Orient Europharma. market cap?▼
Today Orient Europharma. has the market capitalization of 3.69B
What is Orient Europharma. revenue for the last year?▼
Orient Europharma. revenue for the last year amounts to 4.6B TWD.
What is Orient Europharma. net income for the last year?▼
4120.TWO net income for the last year is -567.39M TWD.
Does Orient Europharma. pay dividends?▼
Yes, 4120.TWO dividends are paid annual. The last dividend per share was 4 . As of today, Dividend Yield (FWD)% is 9.36%.
How many employees does Orient Europharma. have?▼
As of November 4, 2026, the company has 339 employees.
In which sector is Orient Europharma. located?▼
Orient Europharma. operates in the Health & Wellness sector.
When did Orient Europharma. complete a stock split?▼
The last stock split for Orient Europharma. was on July 28, 2010 with a ratio of 1.16:1.
Where is Orient Europharma. headquartered?▼
Orient Europharma. is headquartered in Taipei, Taiwan.